Musings from The Power List: Piers Ingram
Piers Ingram discusses the resurgence of immunology, engineering-led drug discovery, and why faster clinical execution will shape the next generation of medicines
False
Piers Ingram discusses the resurgence of immunology, engineering-led drug discovery, and why faster clinical execution will shape the next generation of medicines
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
October 20, 2026
4 min read
Regeneron Genetics Center’s Luca Lotta explains how population-scale genetic evidence can reveal more promising drug targets and open new possibilities for disease prevention
October 20, 2026
4 min read
Piers Ingram discusses the resurgence of immunology, engineering-led drug discovery, and why faster clinical execution will shape the next generation of medicines
October 20, 2026
5 min read
John Wichelt discusses Kindeva’s Bridgeton facility, supporting injectable programs from clinical development through commercial manufacturing, and choosing a long-term fill-finish partner
October 16, 2026
1 min read
Nucleome Therapeutics CTO Jonny Wray reveals how an engineer’s mindset can help navigate the complexity of human biology
False
Affiliations:
Specialties:
Areas of Expertise: